🏛️ Verified NIH Record • Updated 2026-03-25
Immune and Genomic Markers in ALK+ NSCLC (NCT04881916)
Elucidating Novel Immune and Genomic Markers for ALK (ENIGMA+)
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Massachusetts General Hospital
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Anaplastic Lymphoma Kinase Gene Translocation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.